Evidence map›Paper›PMID 34250764›Full record

ArticlePharmacology research & perspectives2021

Ocular safety of repeated intravitreal injections of Carboplatin and Digoxin: A preclinical study on the healthy rabbits.

Alireza Khodabande, Fariba Ghassemi, Fahimeh Asadi Amoli, Hamid Riazi-Esfahani, Raziyeh Mahmoudzadeh, Mohammad Mehrpour, Niloufar Valipour

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Addition of intravitreal carboplatin with melphalan for management of vitreous seeding in retinoblastoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Alireza KhodabandeEye Research Center, Farabi Eye Hospital, Tehran University of Medical Science (TUMS), Tehran, Iran.
Fariba GhassemiEye Research Center, Farabi Eye Hospital, Tehran University of Medical Science (TUMS), Tehran, Iran.
Fahimeh Asadi AmoliEye Research Center, Farabi Eye Hospital, Tehran University of Medical Science (TUMS), Tehran, Iran.
Hamid Riazi-EsfahaniEye Research Center, Farabi Eye Hospital, Tehran University of Medical Science (TUMS), Tehran, Iran.
Raziyeh MahmoudzadehEye Research Center, Farabi Eye Hospital, Tehran University of Medical Science (TUMS), Tehran, Iran.
Mohammad MehrpourEye Research Center, Farabi Eye Hospital, Tehran University of Medical Science (TUMS), Tehran, Iran.
Niloufar ValipourEye Research Center, Farabi Eye Hospital, Tehran University of Medical Science (TUMS), Tehran, Iran.ORCID 0000-0003-2668-6904
University of Tehran · IRThomas Jefferson University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the ocular safety of intravitreal carboplatin and digoxin injections as a new intravitreal chemotherapy option for retinoblastoma tumor vitreous seeds. Eighteen rabbits were divided randomly into three groups to receive intravitreal injection of Digoxin (6 rabbits), Carboplatin (7 rabbits), or Saline (5 rabbits). In every group, one eye randomly treated with 10 µg Digoxin in 0.1 cc or 1 µg Carboplatin or Saline, and the contralateral eye was considered as the control. All groups underwent three consecutive injections of the drugs with 1-week intervals. Baseline electroretinography (ERG) was recorded from both eyes of all the animals prior to injection and was repeated 1st day, 1st week, and 1st month after the last injection. All rabbits were sacrificed 1 month after the last injection, and histological studies were done. Mean a and b wave amplitudes decreased significantly at 1st day, 1st week, and 1st month after the last intravitreal injection of 10 µg Digoxin in comparison with other groups (p-value: .02). Contradictory, 1 µg Carboplatin injected eyes had minimal ERG changes. There were some nonspecific ERG changes with unclear clinical significance in non-injected contralateral control eyes of Digoxin and Carboplatin groups in comparison with the control eyes of the Saline group. Histological studies revealed considerable neural retinal atrophy in injected eyes of the Digoxin group. Intravitreal 10 µg Digoxin might have more local ocular toxicity in comparison with intravitreal Carboplatin in albino rabbit eyes. Future studies should assess the induced toxicity of intravitreal injection of these drugs on the non-injected contralateral eye.

Indexed as

AnimalsAntineoplastic AgentsCarboplatinDigoxinIntravitreal InjectionsRabbitsRetinaRetinoblastomaAntineoplastic AgentsCarboplatinDigoxincarboplatindigoxinintravitreal injectionrabbitsretinoblastoma

Identifiers

PMID34250764
PMCPMC8273607
OpenAlexW3179213400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.